Diagnostic utility of fusion 18F-fluorodeoxyglucose positron emission tomography/cardiac magnetic resonance imaging in cardiac sarcoidosis

[1]  Y. Iwanaga,et al.  Right ventricular involvement is an important prognostic factor and risk stratification tool in suspected cardiac sarcoidosis: analysis by cardiac magnetic resonance imaging , 2019, Clinical Research in Cardiology.

[2]  Y. Kihara,et al.  JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis　- Digest Version. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[3]  Akshay S. Desai,et al.  Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. , 2019, Circulation. Cardiovascular imaging.

[4]  M. Soussan,et al.  Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. , 2019, Clinical radiology.

[5]  T. Ohira,et al.  Prognostic impact of the integration of volumetric quantification of the solid part of the tumor on 3DCT and FDG-PET imaging in clinical stage IA adenocarcinoma of the lung. , 2018, Lung cancer.

[6]  A. Barnes,et al.  Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis , 2018, European heart journal cardiovascular Imaging.

[7]  M. Cerqueira,et al.  Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18F-FDG PET Scans for Suspected Cardiac Sarcoidosis. , 2017, JACC. Cardiovascular imaging.

[8]  V. Fuster,et al.  Nuclear cardiology in the literature: A selection of recent, original research papers , 2018, Journal of Nuclear Cardiology.

[9]  D. Okada,et al.  Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis , 2018, Circulation. Cardiovascular imaging.

[10]  L. Cooper,et al.  Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring , 2017, Journal of Nuclear Cardiology.

[11]  R. Blankstein,et al.  Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation , 2017, Journal of Nuclear Cardiology.

[12]  Takao Kato,et al.  Risk stratification for major adverse cardiac events and ventricular tachyarrhythmias by cardiac MRI in patients with cardiac sarcoidosis , 2016, Open Heart.

[13]  M. Miyagawa,et al.  Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. , 2015, International journal of cardiology.

[14]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[15]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[16]  E. Miller,et al.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis , 2014, Journal of Nuclear Cardiology.

[17]  Keiichiro Yoshinaga,et al.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology Recommendations , 2014, Annals of Nuclear Medicine.

[18]  Jon Hainer,et al.  Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. , 2012, Journal of the American College of Cardiology.

[19]  Subha V Raman,et al.  Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. , 2014, American journal of respiratory and critical care medicine.

[20]  U. Kramer,et al.  CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. , 2013, JACC. Cardiovascular imaging.

[21]  Allison R. Schulman,et al.  18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis , 2013, Current cardiology reports.

[22]  Allison R. Schulman,et al.  18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis , 2013, Current Cardiology Reports.

[23]  Robert A. deKemp,et al.  The Use of 18F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience , 2012, The Journal of Nuclear Medicine.

[24]  J. Ridgway,et al.  Cardiovascular magnetic resonance physics for clinicians: part II , 2010, Journal of Cardiovascular Magnetic Resonance.

[25]  T. Imaizumi,et al.  Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. , 2010, JACC. Cardiovascular imaging.

[26]  J. Ridgway.  Cardiovascular magnetic resonance physics for clinicians: part I , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[27]  M. Nishimura,et al.  Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  E. Kasper,et al.  A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. , 2005, American heart journal.

[29]  M. Nishimura,et al.  Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. , 2005, European heart journal.

[30]  W. Dassen,et al.  Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. , 2005, Journal of the American College of Cardiology.